Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05058651 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 379 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Site details revised at 2 of 263 sites
  3. Study sites: 261 to 263
  4. Recruitment resumed after suspension Trial sites expanded: 255 → 261 locations Show 1 more changeShow less
    • Trial sites expanded: 255 → 261 locations
  5. Re-verified, no change to tracked fieldsv375
  6. Recruitment suspended Sponsor's reason: End of Initial Phase of Multi-phase protocol Site details revised at 255 of 255 sitesv374 Show 1 more changeShow less
    • Site details revised at 255 of 255 sites
  7. Trial sites expanded: 250 → 255 locationsv373
  8. Site details revised at 1 of 250 sitesv372
  9. Study sites revised (250)v371 See this version in full on ClinicalTrials.gov ↗
  10. Site details revised at 1 of 250 sitesv370
  11. Site details revised at 4 of 250 sitesv369
  12. Study sites: 249 to 250v368
  13. Site details revised at 1 of 249 sitesv367
  14. Site details revised at 1 of 249 sitesv366
  15. Study sites: 248 to 249v365
  16. Site details revised at 4 of 248 sitesv364
  17. Trial sites expanded: 245 → 248 locationsv363
  18. Site details revised at 2 of 245 sitesv362
  19. Study sites: 244 to 245v361
  20. Site details revised at 19 of 244 sitesv360
  21. Site details revised at 18 of 244 sitesv359
  22. Site details revised at 4 of 244 sitesv358
  23. Site details revised at 1 of 244 sitesv357
  24. Site details revised at 2 of 244 sitesv356
  25. Study sites: 243 to 244v355
  26. Site details revised at 1 of 243 sitesv354
  27. Site details revised at 1 of 243 sitesv353
  28. 8 versions Re-verified since Apr 1, 2026, no change to tracked fieldsv345-v352
  29. Study sites: 242 to 243v344
  30. Study sites: 240 to 242v343
  31. 7 versions Re-verified since Mar 19, 2026, no change to tracked fieldsv336-v342
  32. Study Status, Contacts/Locationsv335
  33. 5 versions Re-verified since Mar 10, 2026, no change to tracked fieldsv330-v334
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.
Trial Details
NCT Number NCT05058651
Lead Sponsor National Cancer Institute (NCI)
Conditions Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Enrollment 189 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov